TY - JOUR
T1 - The determinants of tumour immunogenicity
AU - Blankenstein, Thomas
AU - Coulie, Pierre G.
AU - Gilboa, Eli
AU - Jaffee, Elizabeth M.
PY - 2012/4
Y1 - 2012/4
N2 - Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.
AB - Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.
UR - http://www.scopus.com/inward/record.url?scp=84858797296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858797296&partnerID=8YFLogxK
U2 - 10.1038/nrc3246
DO - 10.1038/nrc3246
M3 - Review article
C2 - 22378190
AN - SCOPUS:84858797296
SN - 1474-175X
VL - 12
SP - 307
EP - 313
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 4
ER -